The following trials provide information to treat various types of gastrointestinal diseases, both for ongoing and completed clinical trials. For more information on this therapy area please click here.
- collapse To investigate if the market capsule and the phase III capsule of 20 mg H 199/18 are bioequivalent following single dose administration under fasting conditions.
- collapse A bioequivalence study comparing a H 199/18 market capsule, 40 mg, with the H 199/18 phase III capsule, 40 mg following single dose administration under fed conditions in healthy male and female subjects
- collapse A bioequivalence study comparing a H 199/18 market capsule, 40 mg, with the H 199/18 phase III capsule, 40 mg following single and repeated administration under fasting conditions in healthy male and female subjects
- collapse A comparative efficacy and safety study of H 199/18 (20 mg), H 199/18 (40 mg) vs. placebo in study subjects with symptomatic GERD
- collapse A comparative efficacy and safety study of H 199/18 (20 mg), H 199/18 (40 mg) vs. placebo in study subjects with symptomatic GERD
- collapse A comparative efficacy and safety study off H 199/18 40 mg and omeprazole 20 mg in study subjects with erosive esophagitis
- collapse A pharmacodynamic study comparing a 20 mg MUPS tablet with a 20 mg capsule of H 199/18 in patients with symptomatic gastroesophageal reflux disease
- collapse A food interaction study regarding effect on intragastric pH following treatment with H 199/18 tablets in healthy male and female subjects
- collapse An interaction study betweeen H 199/18 and phenytoin in epileptic patients
- collapse A food interaction study regarding pharmacokinetics and effect on intragastric pH following treatment with H 199/18 capsules in healthy male and female subjects
